Using insulin degludec combined with liraglutide (IDegLira) as initial injectable therapy in patients with type 2 diabetes (T2D) who were uncontrolled on oral antidiabetic drugs significantly delays the need for treatment intensification compared with insulin glargine 100 U/mL (IGlar U100) alone, the DUAL VIII study shows.
Cardiovascular (CV) outcomes were similar between the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride in the CAROLINA* study of patients with early type 2 diabetes (T2D) and increased CV risk.
A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.
Patients with youth-onset type 2 diabetes (T2D) are more likely to have an increased rate of cardiovascular (CV), kidney, eye, nerve, and pregnancy complications as they transition to early adulthood, according to the longest-running TODAY*2 study presented at ADA 2019.
The SGLT2* inhibitor dapagliflozin significantly reduced the risk of kidney disease progression or renal death in a large cohort of patients with type 2 diabetes (T2D), according to a sub-analysis of renal data from the phase III DECLARE-TIMI 58** trial reported at ADA 2019.
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.
Continuous glucose monitors (CGMs) are valuable tools for controlling type 1 diabetes among children and young adults, as well as for improving patient satisfaction with diabetes care, according to two studies presented in a joint symposium at the recently concluded 79th Scientific Sessions of the American Diabetes Association at the Moscone Convention Center in San Francisco.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.